Home/Filings/4/0001415889-24-016993
4//SEC Filing

Gillies Hunter 4

Accession 0001415889-24-016993

CIK 0001798749other

Filed

Jun 13, 8:00 PM ET

Accepted

Jun 14, 6:00 PM ET

Size

8.8 KB

Accession

0001415889-24-016993

Insider Transaction Report

Form 4
Period: 2024-06-13
Gillies Hunter
Chief Medical Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2024-06-13$2.14/sh+6,000$12,84011,602 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2024-06-136,00083,510 total
    Exercise: $2.14Exp: 2031-04-01Common Stock (6,000 underlying)
  • Sale

    Common Stock

    2024-06-13$24.50/sh6,000$147,0005,602 total
Footnotes (2)
  • [F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023.
  • [F2]A total of 109,640 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, with shares vesting in 48 substantially equal monthly installments.

Issuer

Aerovate Therapeutics, Inc.

CIK 0001798749

Entity typeother

Related Parties

1
  • filerCIK 0001868997

Filing Metadata

Form type
4
Filed
Jun 13, 8:00 PM ET
Accepted
Jun 14, 6:00 PM ET
Size
8.8 KB